Abstract
Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Cancer Research |
Vol/bind | 16 |
Udgave nummer | 10 |
Sider (fra-til) | 2872-80 |
Antal sider | 9 |
ISSN | 1078-0432 |
DOI | |
Status | Udgivet - 15 maj 2010 |